MIR17HG蛋白表达作为脑膜瘤潜在治疗靶点的研究
本研究测量了25例脑膜瘤组织与21例正常脑膜组织中的MIR17HG蛋白水平,发现脑膜瘤组织MIR17HG蛋白水平显著高于对照组(P=0.012),WHO I级和II级脑膜瘤均显著高于对照组。作者认为MIR17HG可能是脑膜瘤的新治疗靶点,并将为后续研究提供线索。
要点
- 脑膜瘤组织MIR17HG蛋白水平显著高于正常脑膜组织(P=0.012)。
- WHO I级和II级脑膜瘤MIR17HG蛋白水平均显著高于对照组(P=0.026和P=0.042)。
- 以MIR17HG蛋白>0.0998 ng/mL为截断值,脑膜瘤组灵敏度73.91%、特异度69.23%、AUC 0.756。
核心结论
- 本研究中脑膜瘤组织的MIR17HG蛋白表达水平高于正常脑膜组织。
- 考虑到部分脑膜瘤会复发且无法切除、需要进一步治疗,MIR17HG可能是脑膜瘤的新治疗靶点,本研究将为后续研究提供线索。
研究设计与样本
- 测量46份样本的MIR17HG蛋白水平,包括手术获取的25份脑膜瘤组织和死亡后4小时内尸检获取的21份正常脑膜组织。
- 每份样本储存于-80°C,采用夹心酶联免疫分析原理评估MIR17HG蛋白。
- 结果在组间进行比较。
主要发现
- 脑膜瘤组织MIR17HG蛋白水平显著高于对照组,差异有统计学意义(P=0.012)。
- WHO I级脑膜瘤MIR17HG蛋白水平高于对照组,差异有统计学意义(P=0.026)。
- WHO II级脑膜瘤MIR17HG蛋白水平高于对照组,差异有统计学意义(P=0.042)。
- 以MIR17HG蛋白>0.0998 ng/mL为截断值区分脑膜瘤与对照组时,脑膜瘤组灵敏度73.91%、I级71.43%、II级77.78%,脑膜瘤组AUC 0.756、I级0.753、II级0.761,各组特异度均为69.23%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MIR17 host gene (MIR17HG) is a potential therapeutic target for some cancer types. The aim of this study was to assess MIR17HG protein levels in patients with meningioma who had not been reported previously in the literature and comparing with normal meninges tissues. METHODS: MIR17HG protein levels were measured in 46 samples including 25 meningioma tissues procured during surgery and 21 normal meninges tissues obtained within 4 hours of death during autopsy procedures. Each sample was stored at -80°C until the evaluation of MIR17HG protein using a sandwich enzyme-linked immunoassay principle. Results were compared between the groups. RESULTS: MIR17HG protein levels were significantly higher in meningioma tissues compared with controls and difference was statistically significant (P = 0.012). Both World Health Organization grade I and grade II meningiomas had higher MIR17HG protein levels compared with controls and differences were statistically significant (P = 0.026 for grade I and P = 0.042 for grade II). Receiver operating characteristic curve analysis was performed to determine the cutoff of MIR17HG protein value in differentiating meningioma and control groups. At the cutoff value for MIR17HG protein of >0.0998 ng/mL, the sensitivity was 73.91%, 71.43%, and 77.78% and area under the curve was 0.756, 0.753, and 0.761 for meningioma group, grade I, and grade II subgroups, respectively, and specificity was 69.23% for each group. CONCLUSIONS: MIR17HG protein expression was found to have a higher level in meningiomas than in normal meninges tissues in our study. Considering the recurrence and irresectability for some meningiomas, which require further treatment, MIR17HG may be a new target for treatment in meningiomas and our study will shed light on further studies.
引用
- Evran S, Baran O, Kayhan A, et al. The Expression of MIR17HG Protein as a Potential Therapeutic Target in Meningioma. World Neurosurg. 2020. PMID: 32068173. doi:10.1016/j.wneu.2020.02.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。